Takeda Pharmaceutical Co. $TAK Shares Sold by Ethic Inc.

Key Points

• Ethic Inc. has reduced its stake in Takeda Pharmaceutical Co. by 32.7%, selling 106,772 shares and now holds 219,535 shares worth approximately $3.27 million.
• Several other institutional investors have altered their positions in Takeda, with GAMMA Investing LLC increasing its stake by 22.6% and Vontobel Holding Ltd. acquiring a new stake valued at around $262,000.
• Takeda Pharmaceutical reported earnings of $0.52 per share, beating estimates, but its revenue of $7.45 billion fell short of expectations of $7.96 billion.

Ethic Inc. trimmed its holdings in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 32.7% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 219,535 shares of the company's stock after selling 106,772 shares during the period. Ethic Inc.'s holdings in Takeda Pharmaceutical were worth $3,271,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Soleus Capital Management L.P. increased its position in shares of Takeda Pharmaceutical by 136.0% during the 4th quarter. Soleus Capital Management L.P. now owns 1,180,000 shares of the company's stock worth $15,623,000 after purchasing an additional 680,000 shares during the last quarter. Toronto Dominion Bank purchased a new position in Takeda Pharmaceutical during the fourth quarter worth about $6,760,000. BNP Paribas Financial Markets increased its position in shares of Takeda Pharmaceutical by 15,449.0% during the fourth quarter. BNP Paribas Financial Markets now owns 500,677 shares of the company's stock valued at $6,629,000 after acquiring an additional 497,457 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Takeda Pharmaceutical during the fourth quarter valued at about $5,915,000. Finally, ABC Arbitrage SA purchased a new stake in shares of Takeda Pharmaceutical in the 1st quarter valued at approximately $4,994,000. Hedge funds and other institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Trading Up 1.8%

Shares of NYSE:TAK traded up $0.2750 during mid-day trading on Wednesday, reaching $15.4750. 3,275,109 shares of the company were exchanged, compared to its average volume of 2,551,147. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59. The firm has a market cap of $49.24 billion, a price-to-earnings ratio of 51.58 and a beta of 0.22. The firm's 50-day simple moving average is $14.79 and its 200 day simple moving average is $14.64. Takeda Pharmaceutical Co. has a 1 year low of $12.80 and a 1 year high of $15.56.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The company had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Equities research analysts forecast that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.